Eli Lilly’s oral GLP-1RA hits endpoints, but trails Novo’s Wegovy in weight loss
Orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral therapy showed a 13.6% drop in weight.

Orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral therapy showed a 13.6% drop in weight.
Experts discuss the use of artificial intelligence (AI) and patient-centric strategies in oncology clinical trials.
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Pharma’s AI prospects get nudged into the future with EU’s AI act
Are regulators keeping pace with AI adoption in clinical trials?
AI-automated IVF procedures represent a new era in fertility treatment
Eli Lilly and BigHat Biosciences ink AI antibody discovery deal